New Oral Biologic Medication Reduces Precancerous Polyp Formation In The Colon

New Oral Biologic Medication Reduces Precancerous Polyp Formation In The Colon
Animal study results reported by researchers at the University at Buffalo School of Medicine and Biomedical Sciences and covered in a UB News release show that a new oral biologic medication has successfully treated chronic, precancerous intestinal inflammation. Featured on the cover of the current issue of the American Association for Cancer Research's eponymously-named journal Cancer Research, and published online ahead of print in September, the UB study, whose first author is a UB MD/PhD student, the study's findings are characterized by the journal's editors as "striking." Entitled "Oral Interleukin-10 Alleviates Polyposis via Neutralization of Pathogenic T-Regulatory Cells" (Cancer Res October 1, 2014 74:5377-5385; Published Online First September 16, 2014; dpi:10.1158/0008-5472.CAN-14-0918 ), the study is coauthored by Allen Y. Chung, Qingsheng Yijun, Sun Li, Thomas F. Conway, Lauren P. Virtuoso, Nicholas G. Battaglia, Sarah J. Blair, and Nejat K. Egilmez of the Department of Microbiology and Immunology at the University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York; Magdia De Jesus and Nicholas J. Mantis of the Division of Infectious Diseases, Wadsworth Center, Albany, New York; Kristen L. Dennis and Khashayarsha Khazaie of the Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Charles LeVea of the Department of Surgical Pathology, Roswell Park Cancer Institute, Buffalo, New York; Jin Yao of the Department of Electrical and Computer Engineering, University of Florida, Gainesville, Florida (also associated with UB); and Stacia Furtado and Edith Mathiowitz of the Department of Molecular Pharmacology, Physiology & Biotechnology, Brown University, Providence, Rhode Island. K. Kha
Subscribe or to access all post and page content.